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s 13 (2014) 494Journal of Cystic FibrosiNewsStudies of lumacaftor in combination with ivacaftor in people
with cystic fibrosis and homozygous for F508del. Treatment with
the two CFTR modulators (corrector + potentiator) showed
improvement in lung function (i.e. FEV1) in a phase 2 study
(Lancet Respir Med 2014; 2: 527–538). This led to the phase
3 studies of the same combination; a press release reported
statistically significant improvement in FEV1 as well as a
reduction in the frequency of pulmonary exacerbations. Although
the treatment effect for FEV1 was modest (2.6–4.0%), the results
were similar in the two studies and there were consistent results in
the key secondary endpoints. It is anticipated that submissions for
approval with regulatory agencies in the US and Europe will
occur later in 2014 (http://investors.vrtx.com/releasedetail.cfm?
ReleaseID=856185).
Ataluren does not meet its primary endpoint for the treatment
of nonsense-mutations in cystic fibrosis. A placebo-controlled
phase 3 trial did not demonstrate a significant difference in
relative change from baseline in percent-predicted FEV1 nor in
the number of pulmonary exacerbations between the groups.
Post-hoc analysis suggests that there could be a difference in
those patients who are not using inhaled tobramycin, but further
studies would be necessary to dissect this (Lancet Respir Med
2014; 2: 539–547).
Events
North American Cystic Fibrosis Conference, October 8–11,
2015, Atlanta, Georgia.
38th European CF Conference, June 10–13, Brussels,
Belgium.
People
Kris De Boeck named President-elect for ECFS. Dr. De Boeck
is an internationally leading pediatrician researcher and leader
of many international clinical trials who has demonstrated
outstanding leadership in the field of CF and commitment to
the European CF Society. She was the founding director of the
European Clinical Trials Network. Her nomination letters
described her as “an exceptional communicator and educator”
and having “an almost unique ability to build bridges and quite
simply, to make things happen. Her enthusiasm is infectious,http://dx.doi.org/10.1016/j.jcf.2014.07.008catalyzing action by those around her.” She will assume the role
of ECFS President at the ECFC in 2015.
Prof. Kris De Boeck, Belgium
The 2014 ECFS Award was presented to Professor Eitan
Kerem (Israel) to acknowledge his substantial and remarkable
contribution to cystic fibrosis care over 30 years. Prof. Kerem
was born in Jerusalem and graduated from the Hebrew
University-Hadassah Medical School. He completed a fellow-
ship in pediatric respiratory disease at the Hospital for Sick
Children in Toronto, Canada. In 2005 he founded the Center for
Chronic Diseases in Children located at the Hadassah Medical
Center Mount Scopus, a unique clinic which integrates the
services needed for the treatment of chronically ill children. He
has made considerable contributions to the CF field through his
scientific research and was a Board member of the European
Cystic Fibrosis Society, playing a key role in the development
of the European CF Registry. He was the leader of the first
ECFS consensus on Standards of Care for people with CF. He
has also been instrumental in developing models of care and
establishing training programs for health care professionals for
people with CF in Palestine.
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